Impact of Clinical Pharmacists in the Inflammatory Bowel Disease Clinic
Journal of Pharmacy Practice · 2025
DOI: 10.1177/08971900241264339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Ashley Lopez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus OH, USA. Hauptthemen laut MEDLINE: Pharmacists, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Background
Limited evidence exists regarding pharmacist involvement and impact in inflammatory bowel disease (IBD) interdisciplinary clinic care models. The purpose is to describe pharmacist utilization in an interdisciplinary IBD clinic and evaluate clinical impact on patient quality of life.
Methods
This was a retrospective cohort study comparing outcomes in patients with Crohn’s disease initiated on therapy when the implementation of pharmacy services began (Early Phase) to the expansion of pharmacy services (Recent Phase). The primary outcome compared the proportion of patients referred to a pharmacist and those achieving a Harvey-Bradshaw Index (HBI) reduction of ≥3 points after therapy initiation.
Results
50 patients were included in the Early Phase and 43 patients in the Recent Phase. Utilization in pharmacy referrals increased from 48% (n = 24) in the Early Phase to 72% (n = 31) in the Recent Phase ( P = 0.03). The proportion of patients achieving a HBI reduction of ≥3 points increased from 35% (n = 14) in the Early Phase to 51% (n = 18) in the Recent Phase ( P = 0.23). Results also found a greater proportion of patients remaining steroid free in the Recent Phase compared to the Early Phase (50% vs 63%; P = 0.01) and C-reactive protein (CRP) improved significantly in the Recent Phase (−11) compared to (−3) in the Early Phase ( P = 0.006).
Conclusion
The utilization of pharmacists in an interdisciplinary IBD clinic increased and showed to impact patient care through improving symptom relief as seen by the achievement rate of the HBI score reduction, reducing steroid use after therapy initiation, and making clinically significant interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus OH, USA.
ORCID-Profile: Ashley Lopez, Aaron Bagnola
Zitieren
APA
Lopez, A., Snider, M., McFerran, A., Holland, A., Bagnola, A., Mellet, J., Li, J., & Butnariu, M. (2025). Impact of Clinical Pharmacists in the Inflammatory Bowel Disease Clinic. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241264339
Vancouver
Lopez A, Snider M, McFerran A, Holland A, Bagnola A, Mellet J, et al. Impact of Clinical Pharmacists in the Inflammatory Bowel Disease Clinic. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241264339
BibTeX
@article{Lopez2025,
author = {Lopez, Ashley and Snider, Melissa and McFerran, Allison and Holland, Ariel and Bagnola, Aaron and Mellet, John and Li, Junan and Butnariu, Madalina},
title = {Impact of Clinical Pharmacists in the Inflammatory Bowel Disease Clinic},
journal = {Journal of Pharmacy Practice},
year = {2025},
doi = {10.1177/08971900241264339}
}
EUVIMED